Ketamine's Rapid Dissociative and Amnestic Properties Complicate Evidence in Cornell Sexual Assault Allegation

The New York Times account details how ketamine, an NMDA receptor antagonist, induces dissociation and anterograde amnesia within minutes at sub-anesthetic doses. In the Cornell case, the complainant reported effects consistent with 0.5–1 mg/kg intravenous or intramuscular exposure, impairing capacity to resist or recall events. Unlike longer-acting benzodiazepines, ketamine clears rapidly, leaving limited toxicological windows and forcing reliance on circumstantial and witness evidence.

Observational data from emergency toxicology networks show ketamine detections in sexual assault cases rising from 1.2% in 2018 to 3.8% in 2024 across U.S. urban centers, per a 2025 multicenter chart review in JAMA Network Open. This increase tracks expanded veterinary and compounded pharmacy access rather than pharmaceutical diversion. Legal proceedings now confront the same evidentiary gaps previously documented with GHB, where victims present without clear injury and standard panels miss the compound.

Public health implications extend beyond individual prosecution. Ketamine’s growing use in outpatient depression clinics and recreational markets creates overlapping supply chains that reduce traceability. Regulatory responses remain fragmented: the DEA classifies it Schedule III, yet state-level veterinary controls lag. Victim advocacy groups note that current forensic protocols underestimate ketamine’s role because metabolite testing is not routine.

Next steps require standardized inclusion of ketamine and norketamine assays in sexual assault kits plus prospective surveillance through the National Drug Early Warning System. Without these, prevalence estimates and prosecution success rates will remain underpowered.